0IV3.LSE Geron Corp.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -18.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0IV3.LSE undervalued?
Graham numberThe Graham number of Geron Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Geron Corp. fundamental analysis
No fundamental analysis for Geron Corp. yet.
Geron Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Geron Corp.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment …
Full company profileGeron Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Geron Corp. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.16M | 1.07M | 1.07M | 460K | 253K | 1.39M | 596K | 237K | 77.0M | 184M | 219M |
| Gross Profit | -8.53M | -7.37M | -11.7M | -50.8M | -49.8M | 610K | -272K | -124M | 75.7M | 179M | 197M |
| Operating Income | -30.6M | -29.3M | -31.1M | -72.5M | -76.9M | -114M | -139M | -194M | -174M | -51.6M | -25.8M |
| EBITDA | -30.6M | -29.2M | -31.0M | -72.4M | -73.9M | -112M | -134M | -194M | -155M | -50.3M | -24.5M |
| Net Income | -29.5M | -27.9M | -27.0M | -68.5M | -75.6M | -116M | -142M | -184M | -175M | -83.5M | -40.6M |
| EPS | -0.19 | -0.18 | -0.15 | -0.36 | -0.28 | -0.35 | -0.37 | -0.32 | -0.27 | -0.13 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 130M | 110M | 185M | 166M | 271M | 226M | 191M | 394M | 594M | 571M | 519M |
| Total Liabilities | 7.87M | 6.52M | 7.55M | 30.4M | 59.8M | 99.6M | 111M | 146M | 314M | 347M | 300M |
| Shareholders' Equity | 122M | 104M | 178M | 135M | 211M | 126M | 80.0M | 248M | 280M | 226M | 219M |
| Cash & Short-term Investments | 115M | 95.0M | 164M | 140M | 197M | 184M | 173M | 334M | 408M | 360M | 303M |
| Total Debt | - | - | - | 2.55M | 29.7M | 55.0M | 55.8M | 85.9M | 247M | 252M | 252M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.4M | -20.6M | -21.0M | -43.8M | -66.7M | -95.6M | -127M | -168M | -219M | -111M | -157M |
| Capital Expenditure | 57.0K | 16.0K | 16.0K | 413K | 401K | 207K | 431K | 830K | 680K | 49.0K | 950K |
| Free Cash Flow | -18.4M | -20.6M | -21.0M | -44.2M | -67.1M | -95.8M | -128M | -169M | -219M | -111M | -158M |
| Ratios | |||||||||||
| ROE | -24.1% | -26.9% | -15.2% | -50.7% | -35.8% | -91.8% | -177.4% | -74.3% | -62.3% | -37.0% | -18.6% |
| ROA | -22.7% | -25.3% | -14.6% | -41.4% | -27.9% | -51.4% | -74.5% | -46.7% | -29.4% | -14.6% | -7.8% |
| Net Profit Margin | -479.3% | -2,621.2% | -2,534.4% | -14,901.7% | -29,888.1% | -8,335.4% | -23,808.9% | -77,690.7% | -226.7% | -45.4% | -18.6% |
| Debt to Equity | - | - | - | 0.02x | 0.14x | 0.44x | 0.70x | 0.35x | 0.88x | 1.11x | 1.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Geron Corp. dividends
Geron Corp. has not paid dividends in the last 9 fiscal years.
Who owns Geron Corp.
- Insiders 0.08%
- Institutions 77.07%
- Public & others 22.85%
- Free float 556M
Geron Corp. company profile
- Company name
- Geron Corp.
- Ticker
- 0IV3.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 258
- Fiscal year end
- December
- Address
- 919 East Hillsdale Boulevard, Foster City, CA, United States, 94404
- Phone
- 650 473 7700
- Website
- geron.com
About Geron Corp.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corp. management
10- Mr. Harout SemerjianCEO, President & Director · born 1970
- Ms. Michelle J. RobertsonEVP, CFO, Treasurer and Principal Financial & Accounting Officer · born 1967
- Dr. Joseph Emile Eid M.D.Executive VP of Research & Development and Chief Medical Officer · born 1967
- Mr. Ahmed ElNawawiExecutive VP & Chief Commercial Officer · born 1981
- Mr. Shanthakumar TyavanagimattSenior VP & Chief Technical Officer
- Ms. Dawn Schottlandt CFASenior Vice President of Investor Relations & Corporate Affairs
- Mr. Timothy Williams J.D.Executive VP, Chief Legal Officer & Corporate Secretary · born 1977
- Ms. Aron FeingoldVice President of Investor Relations & Corporate Communications
- Ms. Shannon T. OdamExecutive VP & Chief People Officer · born 1975
- Mr. Bryan RidgellSenior VP of Portfolio & Project Management and Chief of Staff